The Role of Urine cytology in the investigation of Haematuria? B Barrass Audit Meeting 17 th May 2006.

Slides:



Advertisements
Similar presentations
Diagnostic tests include: Physical examination Laboratory tests Imaging Endoscopic examination Biopsy Surgery Molecular testing How is cancer diagnosed?
Advertisements

Helical CT Screening for Lung Cancer at Advanced Radiology Consultants
Transitional Cell Carcinoma of the Urinary Tract
NMP22® BladderChek® Test Case Studies. Value of a False Positive Test Result: Case Study #2 Diagnosis: 68 year old male non-smoker Presenting symptom:
Cases in Urological Oncology Dr Manish Patel MB.BS., MMed., FRACS, PhD Urological Cancer Surgeon Westmead Public and Private Hospital Westmead Public and.
Haematuria and Urinary Tract Tumours
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Prostate Cancer Detection in Men with an Initial Diagnosis of Atypical small Acinar Proliferations Dr Charles Chabert The Wollongong Hospital.
Diagnostic Techniques for Endometrial Cancer By:Sara Lotfiyan.
Endoscopic diagnosis of upper-tract TCC – Correlating indications, investigations and histology Finch W, Shah N, Wiseman O Addenbrooke’s Hospital Cambridge.
Ken Chow. What is haematuria?  Macroscopic Visible haematuria Pink or red  Microscopic Gold standard – Microscopy ○ Presence of >3 RBCs per high-powered.
Nipple discharge may occur in a male or in a non-lactating female and is the symptom caused by several situations. In males there is usually an endocrine.
FISH Analysis in Urothelial Cancer Michael Neat, Dr M Mason and Dr A Chandra.
Breast Imaging Made Brief and Simple
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
 The term post menopause is applied to women who have not experienced a menstrual bleed for a minimum of 12 months, assuming that they do still have.
Screening Tests for Brest & Cervical Cancer
Comparative quantitative evaluation of the XIAP, survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients.
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
1 IMPROVED DETECTION AND SURVEILLANCE OF BLADDER CANCER USING A POINT-OF- CARE NMP22 ASSAY Giora Katz MD, Raoul Salup MD, And the NMP22 Clinical Investigation.
Clare Rogers Consultant Breast Surgeon Doncaster and Bassetlaw Hospitals.
بسم الله الرحمن الرحيم. Interpretation of urine cytology Nashwa Emara M.D.,phd ASS. Prof. Pathology.
Adult Medical-Surgical Nursing
In the name of God Isfahan medical school Shahnaz Aram MD.
Should I have that blood test for Prostate Cancer?
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
The Treatment of the Axilla in the North of England Cancer Network. Henry Cain ST7 North Tyneside.
Screening and Diagnostic Testing Sue Lindsay, Ph.D., MSW, MPH Division of Epidemiology and Biostatistics Institute for Public Health San Diego State University.
Improved Detection of Bladder Cancer in Diagnosis and Surveillance Patients Using a Point-of-Care Proteomic Assay Barry Stein, M.D. G. Katz, M.D. NMP22.
PCa Screening New Areas of Research Francesco Montorsi Milan.
Initial Diagnosis of Bladder Cancer Using a Point-of-Care Assay H. Barton Grossman, M.D. and the NMP22 Clinical Investigation Group.
Management of T1G3 Bladder cancer Dr Charles Chabert.
Neoplasms of the bladder
COSULTANT UROLOGIST.  Diseases of lower urinary tract.
The tumour suppressor RhoB is an independent prognostic factor for metastasis in urinary bladder cancer. Apostolos Zaravinos 1, Dimitrios Volanis 1,2,
Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky.
Screening Puja Myles
April 2014 Dr J King Dr K Syred.  90% mesotheliomas are linked to asbestos exposure  May be eligible for compensation  3 yr survival rate 8%  Subtype.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Microscopic Haematuria. Transient Causes Transient –UTI –Exercise Spurious –Menstrual contamination –Sexual intercourse.
Trophoblastic disease -This is a group of disorders characterized by -This is a group of disorders characterized by 1-abnormal placental development. 1-abnormal.
Hematuria Resident Lecture
The One Stop Head and Neck Lump Clinic David Courtney Consultant Maxillofacial Surgeon Derriford Hospital, Plymouth.
Carcinoma of Bladder & Prostate BPH
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Supraclavicular metastasis from urothelial bladder carcinoma: A case report S. Farmahan, T. Mirza, P. Ameerally Oral Maxillofacial Department, Northampton.
Early Diagnosis of Gynaecological Cancer Rob Gornall Consultant Gynaecology GHNHST.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Case 3 75 Yr male. pT1 TCC upper ureter. Smoker CKD stage 2 Diabetic Monday morning. Patient admitted for lap nephroureterectomy. Discuss procedure and.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
Quality issues in monitoring diagnostic and treatment performance Dr
Tips for Inserting Graphs or Images Tips for Title/Headers Bar Color
Haematuria Haematuria is a common condition and one which must be taken seriously. Haernaturia is usually divided into :- - Macroscopic (where the urine.
Prognostic significance of tumor subtypes in male breast cancer:
Poongkodi Nagappan and Supul Hennayake
Endoscopic Treatment of Upper Tract Urothelial Tumours
Screening for Ovarian Cancer
Vesical calculus.
Apollo Gleneagles Hospitals,
An Audit on Complex hyperplasia reporting at Derriford Hospital
SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI
Role of cytokeratins in the diagnosis and prognosis of the bladder cancer Giorgi Adeishvili MD Multiprofile clinic Consilium Medulla.
Airedale NHS Foundation Trust
Standardised follow-up
Suspected Gynaecological Cancer Recognition & Referral
Evidence Based Diagnosis
ERCP for the Diagnosis and Management of PSC
HAEMATURIA (Whistle-stop tour)
Presentation transcript:

The Role of Urine cytology in the investigation of Haematuria? B Barrass Audit Meeting 17 th May 2006

Overview Urine Cytology The Role of cytology in haematuria assessment Audit Standards Aims Methods Results Comparison with Audit stanards Discussion Recommendations

Atypical Malignant

Urine Cytology 1864-Exfoliated urothelial cells first described 1945-First used to diagnose urothelial malignancy Graded I-V (Papanicolaou & Marshal 1945) I-II normal IIIsuspicious IV-Vmalignant Sensitivity 42% - 66% Specificity up to 97%

Problems with Urine Cytology Low grade malignancy less likely shed cells Patients with suspicious cytology faced with: Anxiety over undiagnosed cancer Several invasive investigations and F/U False positive common Stones UTI Radiotherapy Urinary Instrumentation Only 50% with positive cytology have cancer – who should be investigated?

How Should Suspicious Cytology be Followed-up? 2005 Nabi et al followed up 70 patients with haematuria & C3-C5 cytology & normal investigations 25 had normal repeat cytology 4 had persistent suspicious cytology 41 developed cancer in mean 5.6 months 37 had positive repeat cytology 8 had recurrent haematuria 4 had prostate cancer Recommends investigate: Persistent positive cytology Symptoms

Audit Standards 1. Was cytology repeated? 2. Was repeat abnormal cytology investigated? 3. Were investigations thorough Lower tract: -GA cystoscopy Upper tract:-IVU -Retrograde & washing -Ureteroscopy retrograde abnormal

Aims 1. Review the investigations & diagnosis for positive cytology 2. Review additional Investigations to investigate for positive cytology 3. Review if these investigations generated additional diagnosis 4. What was the cost & morbidity of additional tests? 5. How did the results compare with the audit standards? 6. Recommend use and follow-up of cytology in the investigation of haematuria

Methods All urine cytology was reviewed between 01/10/2001 and 31/06/2004 Patients were identified who had C3-5 cytology either No histological diagnosis No repeat cytology Notes were obtained and reviewed Data was recorded regarding Investigations & associated morbidity Diagnosis Follow-up and survival

Results: Patient identification 1829 urine samples analysed 9% were atypical 11% were inadequate 80% were benign. Of the 164 (9%) atypical samples 53 (32%) had urothelial neoplasia 33 (20%) had repeat cytology 14 (8.5%) had other urological / gynaecological malignancy 61 (42.7%) had no further sample or biopsy 3 had missing records 65 (40%) had either no biopsy, no repeated cytology or persistently abnormal cytology

Results: Positive Cytology & Cancer 187 biopsy following urine cytology 53 TCC with benign cytology Atypical cytology identified 42 TCC 1 breast met (bladder) 11 prostate cancer 1 endometrial cancer 1 penile cancer INADEQUATEBENIGNATYPICAL BENIGN CIS/TCC sensitivitySpecificity This study 47%93% Keir&Womak %72% Beyer Boon %92% Raitanen % primary 34% recurrent 90% Amberson & Laino %99%

Results – reason for checking cytology Reason for investigatingNumber% Unknown812.3 microscopic haematuria irritative LUTS34.6 to investigate mets11.5 to investiagte haematuria non specified57.7 to investigate frank haematuria f/u TCC710.8 to investigate haemospermia11.5 to investigate vaginal discharge11.5

Results – Initial Investigation INVESTIGATIONNo.% unknown710.8 Nil34.6 Cystoscopy23.1 flexible cystoscopy GA cyst23.1 USS23.1 CT11.5 INVESTIGATIONNo.% unknown812.3 Nil57.7 IVU46.2 USS / KUB CT23.1 KUB11.5 USS Lower tract Upper tract

Results – Initial Diagnosis Of those with a diagnosis: 7 (33%) had a tumour 14 (66.7%) had a benign diagnosis DIAGNOSISNUMBER% Diagnosis Normal Unknown1624.6

Results – Additional Lower Tract Investigation & diagnosis 11 patients (16.9%) had further investigation 1 (10%) aspirated after GA cystoscopy The remaining 54 (83.1%) had either no further imaging of the lower urinary tract (47) or were unknown (7 ) Initial DiagnosisAdditional InvestigationFindingNo. cystitisGA cystoscopynormal2 GA cystoscopynormal3 Other DiagnosisGA cystoscopyConfirmed5 v-v FistulaMRI / USSNormal1 CTNormal1

Results – Additional Upper Tract Investigation & Diagnosis 9 (13.8%) underwent further upper tract investigations 2 (22.2%) had a diagnosis (ureteric stones) causing stones positive cytology 1 (11.%) had diagnosis (duplex) that did not cause abnormal cytology 6 (66.7%) either had a diagnosis confirmed or were confirmed to be normal. Additional InvestigationNo.% Unknown710.8 Ureteroscopy, retrograde, biopsy, washing11.5 Retrograde23.1 IVU46.2 IVU & retrogrades11.5 IVU RGP ureteroscopy11.5 Nil4975.4

Results: Follow-up Cytology Finding on cytologyNumberInvestigation normal1Not investigated abnormal1 Fully investigated (no diagnosis) abnormal1 Fully investigated (diagnosis) abnormal2Not investigated inadequate1Fully investigated Six patients (9.2%) also had repeat cytology

Results: Overall Additional Diagnostic Yield of Investigating Cytology Lower tract diagnosis Nil Upper tract diagnosis 2 upper ureteric stones 3.1% of total, 22.2% of those investigated (found on retrogrades) No additional malignancies were detected one patient had a serious complication (aspiration) There were four false positives (6.2%) detected on re- investigation 3 found on lower tract imaging and 1 found on cytology

Results: Final Diagnosis after all Investigations 3 patients have unexplained positive cytology of which only one underwent further investigations 54 (83.1%) had no further lower tract imaging and 49 (75.4%) had no further upper tract imaging. DiagnosisNumber% Diagnosis Normal Unknown1624.6

Results: Significance of Frank Haematuria Diagnosis % with frank haematuria Normal35.4 Any diagnosis52.4 Cancer71.4 (100% frank haematuria, non-specified or known cancer)

Follow-up and Outcome The median follow-up 30 months ( months). Mortality 13.8% (9 patients) Disease specific mortality 6.2% (4 patients) All disease specific deaths occurred in patients diagnosed with TCC on initial assessment 2 (50%) had C3-4 cytology and 2 (50%) had C5 cytology 1 recurrence during follow-up (2.3% of those found to be normal or benign on initial assessment) Previous TCC with C5 cytology. An initial flexible cytoscopy was normal Disease free interval 40 months Grade & stage G1Pta TCC This patient did not contribute to the mortality.

Comparison with Audit Standard StandardResult Was cytology repeated?36 (37%) of 97 with no diagnosis had repeat cytology Was abnormal cytology investigated 2 (50%) of 4 with persistently abnormal cytology were investigated Were additional lower tract investigations sufficient 10 (15.4%) had a GA cystoscopy Were additional upper tract investigations sufficient 9 (13.8%) had upper tract investigation and 5 (7.7%) had retrograde or ureteroscopy

Discussion The results were below the standard in terms of repeating positive cytology Investigating positive cytology The investigation of positive cytology was variable Investigation of cytology didn't yield many additional diagnosis over all (3.1%) Did not yield any additional cancers Did yield a high number of diagnosis among those investigated (22.2%) Retrograde yielded all additional diagnosis The presence of frank haematuria seemed to correlate with malignancy C3-4 cytology does not rule out finding tumour The recurrence rate was low and there were no new cancers during follow- up, suggesting most patients were unlikely to have significant cancer Most diagnoses were benign (70% C5 and 93.1 C3/4)

Recommendations 1. Cytology does not seem to increase the diagnosis of malignancy through the haematuria clinic but… Few were investigated Low rate of malignancy during F/U 2. Atypical cytology should be repeated and investigated only if persistently abnormal 3. A prospective study of the long-term follow-up of atypical cytology is needed 1. Do patients with benign diagnosis or cytology that normalises on F/U have any increase in risk? 2. What is the diagnostic yield of full investigation for positive cytology –does it add to the haematuria assessment? 3. Are there any reliable clinical markers that can be used to identify those who should be investigated e.g. frank bleeding?